Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT-TRANSCENTA REPORTS RECEIPT OF HICB OUT-LICENSING MILESTONE PAYMENT AND STEADY CDMO BUSINESS GROWTH
Regulatory Filings Classification · 82% confidence The document is a voluntary business update announcement by a Hong Kong listed company describing receipt of a milestone payment and CDMO business growth. It contains no actual financial statements or formal meeting materials, nor is it announcing share issues, dividends, or management director appointments as the primary focus. It is not an earnings release or regulatory certification but a general corporate update provided to investors. This fits the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT-TRANSCENTA'S PARTNER INHIBRX REPORTS POSITIVE UPDATED CRC DATA FOR OZEKIBART AND ANNOUNCES U.S. BLA SUBMISSION FOR CHONDROSARCOMA
Regulatory Filings Classification · 34% confidence The document is a voluntary corporate announcement providing business updates on clinical trial results and regulatory submissions. It does not present financial statements, dividend notices, capital-raising activities, or board changes. It is not announcing the publication of a formal report, nor is it a transcript or investor presentation. No defined category fits these scientific and regulatory milestone updates except the general regulatory/miscellaneous fallback. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-21 English
POSTPONEMENT OF ANNUAL GENERAL MEETING AND CHANGE OF PERIODS OF CLOSURE OF REGISTER OF MEMBERS
Regulatory Filings Classification · 85% confidence The document is a stock exchange announcement regarding postponement of the Annual General Meeting and the change in closure dates of the register of members. It does not contain AGM materials or minutes (AGM-R), nor actual voting results (DVA), but rather is a general regulatory announcement to the market. It’s not a financial report, management changes, or a formal circular, but a regulatory filing announcement. Therefore, it falls under the miscellaneous Regulatory Filings category (RNS).
2026-05-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 100% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Transcenta Holding Limited. It includes information on authorized and issued share capital, share options, share incentive schemes, and confirmations related to compliance with listing rules. The document is a regulatory submission reporting changes in share capital and share movements for the month ended April 30, 2026. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory filing required by the exchange to disclose share capital movements and related confirmations. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and detail confirm it is not a brief announcement but a formal regulatory return.
2026-05-07 English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED HOLDERS
Report Publication Announcement Classification · 95% confidence The document is a notification letter to registered shareholders announcing the publication of the 2025 Annual Report and 2025 ESG Report, with guidance on accessing the reports online and offering printed versions upon request. It does not contain the financial statements themselves but rather informs shareholders that the reports are available. This fits the definition of a Report Publication Announcement (RPA).
2026-04-28 English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS
Report Publication Announcement Classification · 92% confidence The document is clearly a notification letter to shareholders (Non-registered Holders) that the Company’s 2025 Annual Report and 2025 ESG Report have been published online, with instructions on how to access them or request printed copies. It does not contain the actual report content, but merely announces the publication and distribution method, fitting the definition of a Report Publication Announcement.
2026-04-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.